A Phase 3 interventional study of Part 1 Blinded - AL001 and Part 1 Blinded - Placebo in Frontotemporal Dementia, sponsored by Alector Inc.. Terminated at 44 sites in 16 countries. Open to participants aged 25 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Alector Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 103 studies in Frontotemporal Dementia with a site in United States — 31 open to participants now, 45 under way, none of them phase 3. Frontotemporal Dementia · United States.
Among the 103 studies in Frontotemporal Dementia with a site in United States, this one is the 21st largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2020, is one of 5 in phase 3, and was the 60th registered.
208 studies on the registry are indexed under Frontotemporal Dementia; 72 are open to participants now.
Browse Frontotemporal Dementia studies →31 of the 103 studies in Frontotemporal Dementia with a site in United States are open now. Recruiting first, the newest first:
Institute for Molecular Medicine · Sites in United States
Ages 65–80
Maya Henry · Sites in United States
Ages 40+
Oregon Health and Science University · Sites in United States
Ages 18–100 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 45+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 18–100
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Frontotemporal Dementia studies recruiting now, 29 (57%) set no upper age limit and 5 (10%) stop at 75 or younger; 6 take children under 18; 30 take healthy volunteers.
This study: 25 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
103 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 19 · Phase 3 5 · Phase 4 3
First in 2001; this study’s year is marked. 8 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 50 across 128 interventional studies indexed under Frontotemporal Dementia.
Median enrollment 60 across the 66 interventional studies, 201 across the 37 observational. Of the 52 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 103 have an industry lead sponsor. The 10 most frequent:
Alector Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 5 (50%) have results posted.
Alector Inc. has 4 studies filed under Frontotemporal Dementia — fewer than ten, so there is no comparison to draw.
14 of the studies in Frontotemporal Dementia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05262023Denali Therapeutics Inc.A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN) | 2026-12 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
| NCT03702907Georgetown UniversityDC Longitudinal Study on Aging and Specimen Bank | 2027-01 |
| NCT05184569Peter Ljubenkov, MDVeri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology | 2027-01-31 |
| NCT04516499The Bluefield Project to Cure Frontotemporal DementiaNeurofilament Surveillance Project (NSP) | 2027-02 |
Add all 14 to your calendar (.ics) → With an account.
Among the 103 studies in Frontotemporal Dementia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
This is a phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 administered intravenously in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene. Study completion marks the end of the open label extension period following the 96-week blinded portion of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive AL001 60 mg/kg administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period.
Drug: Part 1 Blinded - AL001
Participants receive placebo administered by intravenous (IV) infusion every 4 weeks during the double-blind treatment period.
Drug: Part 1 Blinded - Placebo
Participants who received AL001 during the double-blind treatment period and enroll in the optional open-label extension receive AL001 60 mg/kg administered by intravenous (IV) infusion every 4 weeks.
Drug: Part 2 (OLE Treatment) - AL001
Participants who received placebo during the double-blind treatment period and enroll in the optional open-label extension receive AL001 60 mg/kg administered by intravenous (IV) infusion every 4 weeks.
Drug: Part 2 (OLE Treatment) - Placebo Switched to AL001
Administered via intravenous (IV) infusion
Administered via intravenous (IV) infusion
Administered via intravenous (IV) infusion
Administered via intravenous (IV) infusion
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo as Measured by the CDR® Plus NACC FTLD-SB in Symptomatic Patients
Part 1 Primary Endpoint - Change from baseline to Weeks 48, 72, and 96 in the CDR® plus NACC FTLD-SB. The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior \& Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24. Higher score indicates severe impairment.
Time frame: Through study completion, on average up to 96 weeks
Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients
Geometric Mean Fold Change from baseline to Week 96 in PGRN concentrations in plasma
Time frame: Baseline to 96 weeks
Part 2 OLE - To Assess the Long-term Safety and Tolerability of AL001 in Participants Who Have Completed Part 1 of the Study
Part 2 OLE Primary Endpoint - Incidence, nature, and severity of AEs and SAEs in Part 2 OLE
Time frame: 96 weeks
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-S
Change from baseline to Weeks 48, 72, and 96 on the CGI-S. The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients. Higher scores indicate worsening.
Time frame: Baseline to 96 weeks
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by CGI-I
Actual values at Weeks 48, 72, and 96 on the CGI-I. The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse. Higher scores indicate worsening.
Time frame: Baseline to 96 weeks
Part 1 Double Blind - Evaluation of Efficacy of AL001 Compared With Placebo in Symptomatic Participants as Measured by Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score
Change from baseline to Weeks 48, 72, and 96 on the RBANS. RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment.
Time frame: Baseline to 96 weeks
Part 1 Double Blind - Evaluation of the Safety and Tolerability of AL001 Compared With Placebo as Measured by Safety Assessments
Incidence of adverse events
Time frame: Baseline to 96 weeks
Part 1 Double Blind: Clinical Progression as Measured by Frontotemporal Dementia Rating Scale (FRS) Logit Score in Symptomatic Participants
The FRS is a 30-item scale with item responses of 'All the time,' 'Sometimes,' 'Never,' or 'Not applicable' for each item. The total percentage score is calculated as the number of items with a response of 'Never,' divided by the number of applicable items, excluding those marked 'not applicable.' The percentage score ranges from 0 to 100, inclusive, with higher scores indicating better function (fewer behavioral/functional problems) and lower scores indicating worse function. The percentage score is converted to a logit score ranging from -6.66 to 5.39 using a look-up table defined as part of the FRS instrument, where a higher (more positive) logit score indicates better function/less disease severity (5.39 = normal) and a lower (more negative) logit score indicates worse function/greater disease severity (-6.66 = advanced/profound impairment). A decrease in logit score over time reflects clinical progression
Time frame: baseline to 96 weeks
Approximately 110 participants were to be enrolled, with a minimum of 90 symptomatic participants. A total of 119 participants were randomized: 103 participants were symptomatic, and 16 participants were non-symptomatic and thus considered "at-risk". In Part 1, participants were randomly assigned to receive latozinemab (60 mg/kg) or placebo in a 3:2 ratio (latozinemab:placebo). In Part 2, all participants received latozinemab 60 mg/kg q4w, regardless of treatment assignment in Part 1.
| Milestone | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Part 2 (OLE Treatment) - AL001 | Part 2 (OLE Treatment) - Placebo Switched to AL001 |
|---|---|---|---|---|
| Started | 72 | 47 | 0 | 0 |
| Completed | 40 | 35 | 0 | 0 |
| Not completed | 32 | 12 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 20 | 6 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 2 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 0 | 0 |
| Withdrew: Death | 2 | 0 | 0 | 0 |
| Withdrew: Randomized not dosed | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 1 | 2 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 0 | 0 |
| Milestone | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Part 2 (OLE Treatment) - AL001 | Part 2 (OLE Treatment) - Placebo Switched to AL001 |
|---|---|---|---|---|
| Started | 0 | 0 | 35 | 28 |
| Completed | 0 | 0 | 10 | 8 |
| Not completed | 0 | 0 | 25 | 20 |
| Withdrew: Physician decision | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 | 5 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 16 | 14 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
Part 1 Primary Endpoint - Change from baseline to Weeks 48, 72, and 96 in the CDR® plus NACC FTLD-SB. The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior \& Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24. Higher score indicates severe impairment.
| score on the scale | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Week 96 Change from Baseline | 9.686 (7.938 to 11.433) | 8.177 (6.469 to 9.885) |
| Week 72 Change from Baseline | 6.765 (5.592 to 7.939) | 5.771 (4.623 to 6.919) |
| Week 48 Change from Baseline | 4.477 (3.617 to 5.337) | 4.628 (3.702 to 5.553) |
Change from baseline to Weeks 48, 72, and 96 on the CGI-S. The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients. Higher scores indicate worsening.
| score on the scale | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Change from Baseline to Week 96 | 1.593 (1.297 to 1.888) | 1.450 (1.170 to 1.730) |
| Change from Baseline to Week 72 | 1.285 (1.049 to 1.521) | 1.176 (0.878 to 1.474) |
| Change from Baseline to Week 48 | 1.019 (0.835 to 1.202) | 0.776 (0.558 to 0.994) |
Actual values at Weeks 48, 72, and 96 on the CGI-I. The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse. Higher scores indicate worsening.
| score on the scale | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Week 96 | 5.734 (5.461 to 6.007) | 5.530 (5.254 to 5.806) |
| Week 72 | 5.373 (5.095 to 5.651) | 5.285 (5.077 to 5.492) |
| Week 48 | 5.201 (5.001 to 5.401) | 5.167 (4.949 to 5.385) |
Change from baseline to Weeks 48, 72, and 96 on the RBANS. RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment.
| score on the scale | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Change from Baseline to Week 96 | -10.578 (-17.240 to -3.917) | -8.012 (-12.038 to -3.986) |
| Change from Baseline to Week 72 | -9.707 (-14.773 to -4.642) | -10.625 (-14.007 to -7.243) |
| Change from Baseline to Week 48 | -10.077 (-12.531 to -7.623) | -11.359 (-15.306 to -7.412) |
Geometric Mean Fold Change from baseline to Week 96 in PGRN concentrations in plasma
| Fold Change | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Part 1 Double Blind (Co-Primary US Endpoint) - Evaluation of the Treatment Effect of AL001 Compared With Placebo as Measured by Pharmacodynamic and Disease Pathology Biomarkers in Symptomatic Patients | 2.267 (2.097 to 2.451) | 0.857 (0.784 to 0.937) |
Incidence of adverse events
| participants | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Any TEAE | 62 | 40 |
| TEAE graded as Severe or higher | 11 | 4 |
| Any Treatment-Emergent Serious AE (TESAE) | 11 | 3 |
| TEAE Leading to Early Study Treatment Discontinuation | 4 | 1 |
| TEAE Leading to Study Treatment Interruption | 6 | 2 |
| TEAE Leading to Death | 2 | 0 |
| Any Treatment-related TEAE | 18 | 11 |
| Treatment-Related TEAE graded as Severe or higher | 1 | 1 |
| Any Treatment-Related TESAE | 1 | 0 |
Part 2 OLE Primary Endpoint - Incidence, nature, and severity of AEs and SAEs in Part 2 OLE
| events | Part 2 (OLE Treatment) - AL001 | Part 2 (OLE Treatment) - Placebo Switched to AL001 |
|---|---|---|
| Any TEAE | 28 | 17 |
| TEAE graded as Severe or higher | 2 | 4 |
| Any Treatment-Emergent Serious AE (TESAE) | 2 | 2 |
| TEAE Leading to Early Study Treatment Discontinuation | 0 | 0 |
| TEAE Leading to Study Treatment Interruption | 1 | 4 |
| TEAE Leading to Death | 1 | 0 |
The FRS is a 30-item scale with item responses of 'All the time,' 'Sometimes,' 'Never,' or 'Not applicable' for each item. The total percentage score is calculated as the number of items with a response of 'Never,' divided by the number of applicable items, excluding those marked 'not applicable.' The percentage score ranges from 0 to 100, inclusive, with higher scores indicating better function (fewer behavioral/functional problems) and lower scores indicating worse function. The percentage score is converted to a logit score ranging from -6.66 to 5.39 using a look-up table defined as part of the FRS instrument, where a higher (more positive) logit score indicates better function/less disease severity (5.39 = normal) and a lower (more negative) logit score indicates worse function/greater disease severity (-6.66 = advanced/profound impairment). A decrease in logit score over time reflects clinical progression
| score on the scale | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo |
|---|---|---|
| Part 1 Double Blind: Clinical Progression as Measured by Frontotemporal Dementia Rating Scale (FRS) Logit Score in Symptomatic Participants | -2.006 (-2.600 to -1.413) | -1.925 (-2.431 to -1.420) |
Collected over Adverse events (AE) were collected from the screening period (up to 6 weeks prior to Day 1) through 10 weeks after the last dose of study drug, for a total duration of up to 112 weeks (planned) for participants completing the planned Part 1 double-blind period (96 weeks) plus follow-up. For participants in Part 2 (OLE), AE collection continued through 10 weeks after their last dose, up to the date of early study termination or completion for a maximum of an additional 106 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1 Blinded - AL001 | 2/72 (2.8%) | 11/72 (15.3%) | 27/72 (37.5%) |
| Part 1 Blinded - Placebo | 0/46 (0%) | 3/46 (6.5%) | 16/46 (34.8%) |
| Part 2 (OLE Treatment) - AL001 | 1/35 (2.9%) | 2/35 (5.7%) | 15/35 (42.9%) |
| Part 2 (OLE Treatment) - Placebo Switched to AL001 | 0/28 (0%) | 2/28 (7.1%) | 11/28 (39.3%) |
| Event | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Part 2 (OLE Treatment) - AL001 | Part 2 (OLE Treatment) - Placebo Switched to AL001 |
|---|---|---|---|---|
| Ischaemic cerebral infarctionNervous system disorders | 0/72 | 0/46 | 0/35 | 1/28 |
| ConstipationGastrointestinal disorders | 0/72 | 0/46 | 0/35 | 1/28 |
| Urinary tract infectionInfections and infestations | 0/72 | 0/46 | 0/35 | 1/28 |
| Haemorrhagic strokeNervous system disorders | 0/72 | 0/46 | 1/35 | 0/28 |
| Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/72 | 0/46 | 1/35 | 0/28 |
| Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/72 | 1/46 | 0/35 | 0/28 |
| Prostatic adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/72 | 1/46 | 0/35 | 0/28 |
| Peripheral venous diseaseVascular disorders | 0/72 | 1/46 | 0/35 | 0/28 |
| Accidental exposure to productInjury, poisoning and procedural complications | 1/72 | 0/46 | 0/35 | 0/28 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/72 | 0/46 | 0/35 | 0/28 |
| Event | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Part 2 (OLE Treatment) - AL001 | Part 2 (OLE Treatment) - Placebo Switched to AL001 |
|---|---|---|---|---|
| COVID-19Respiratory, thoracic and mediastinal disorders | 13/72 | 9/46 | 2/35 | 1/28 |
| Urinary tract infectionInfections and infestations | 10/72 | 8/46 | 5/35 | 5/28 |
| FallInjury, poisoning and procedural complications | 11/72 | 7/46 | 4/35 | 0/28 |
| InfluenzaInfections and infestations | 6/72 | 2/46 | 3/35 | 4/28 |
| InsomniaPsychiatric disorders | 2/72 | 4/46 | 4/35 | 3/28 |
| FatigueGeneral disorders | 8/72 | 1/46 | 1/35 | 0/28 |
| Urinary IncontinenceRenal and urinary disorders | 8/72 | 2/46 | 0/35 | 3/28 |
| HeadacheNervous system disorders | 3/72 | 5/46 | 3/35 | 0/28 |
| NasopharyngitisInfections and infestations | 6/72 | 3/46 | 3/35 | 1/28 |
| AnxietyPsychiatric disorders | 1/72 | 2/46 | 3/35 | 0/28 |
One symptomatic participant was randomized to placebo but never received study treatment. Of the 102 symptomatic participants that received treatment, 63 received latozinemab and 39 received placebo. Of the 16 participants at-risk, 9 received latozinemab and 7 received placebo. A total of 63 participants continued into Part 2 of the study: 35 participants from the latozinemab group and 28 participants from the placebo group.
| Age, Categorical(Participants) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 49 | 30 | 79 |
| >=65 years | 23 | 16 | 39 |
| Sex: Female, Male(Participants) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| Female | 40 | 20 | 60 |
| Male | 32 | 26 | 58 |
| Race (NIH/OMB)(Participants) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 65 | 38 | 103 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 6 | 7 | 13 |
| Ethnicity (NIH/OMB)(Participants) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 61 | 38 | 99 |
| Unknown or Not Reported | 6 | 5 | 11 |
| Region of Enrollment(Participants) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| Argentina | 1 | 0 | 1 |
| United States | 15 | 10 | 25 |
| United Kingdom | 4 | 1 | 5 |
| Portugal | 5 | 7 | 12 |
| Switzerland | 0 | 1 | 1 |
| Spain | 9 | 2 | 11 |
| Greece | 2 | 0 | 2 |
| Canada | 2 | 1 | 3 |
| Netherlands | 3 | 1 | 4 |
| Sweden | 1 | 1 | 2 |
| Turkey | 1 | 2 | 3 |
| Belgium | 2 | 0 | 2 |
| Italy | 20 | 14 | 34 |
| Australia | 0 | 2 | 2 |
| France | 4 | 4 | 8 |
| Germany | 3 | 1 | 4 |
| Handedness(Participants) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| Left Handed | 6 | 1 | 7 |
| Right Handed | 66 | 45 | 111 |
| Height(Centimeters) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| Mean | 169.33 ± 8.972 | 168.86 ± 9.626 | 169.15 ± 9.192 |
| Weight(Kg) | Part 1 Blinded - AL001 | Part 1 Blinded - Placebo | Total |
|---|---|---|---|
| Mean | 77.30 ± 14.429 | 78.05 ± 13.556 | 77.59 ± 14.041 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Sep 2025, 61 months.
Results were first posted in Sep 2026, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alector Inc.